insights_auto
Why is LCTX up 8,70%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
1,03 USD
arrow_upward
+8,70%(+0,082) 1D
1,03 USD
0,00% (0,00)
bedtimeAfter hours
Closed: 8-окт., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
0,95 USD
High
1,04 USD
Low
0,93 USD
Mkt. cap
259,91 млн
Avg. vol.
1,37 млн
Volume
2,01 млн
52-wk high
2,09 USD
52-wk low
0,88 USD
EPS
-0,14 USD
Beta
1,60
Shares outstanding
252,91 млн
No. of employees
75
Open
0,95 USD
High
1,04 USD
Low
0,93 USD
Mkt. cap
259,91 млн
Avg. vol.
1,37 млн
Volume
2,01 млн
52-wk high
2,09 USD
52-wk low
0,88 USD
EPS
-0,14 USD
Beta
1,60
Shares outstanding
252,91 млн
No. of employees
75
News stories
From web sources and news partners
Quiver Quantitative
·
24 мүнөт мурун
Green AI Cloud, Inc. Announces Definitive Business Combination Agreement with Pioneer Acquisition I Corp. to Go Public on Nasdaq
Yahoo Finance
·
1 саат мурун
RoboStrategy to Host Robotics Founders Forum and Ring the Nasdaq Closing Bell with Dyna Robotics Humanoid on October 13
The Globe and Mail
·
13 мүнөт мурун
U.S. Analyst Updates: October 8th, 2026
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc